A Contrastive Meta-analysis of Pathological Complete Response Rate in Neoadjuvant Chemotherapy between Triple-negative Breast Cancer and HER-2 Positive Breast Cancer

Objective To compare the pathological complete response( pCR) rates in neoadjuvant chemotherapy( NAC) between triple-negative breast cancer( TNBC) and human epidermal growth factor receptor 2( HER-2) positive breast cancer so as to provide accurate data for evidence-based medicine. Methods Literature of NAC in treatment of TNBC and HER-2 positive breast cancer was retrieved from the PubMed and Cochrane Collaboration Library databases, and the pCR rate in patients with TNBC and HER-2 positive breast cancer was compared by using relative risk( RR). Results There were 11 literature reviews of 1076 patients,and the pCR rate was 28. 2% in TNBC group,and that in HER-2 positive group was 20. 0%. The summary RR for pCR rate of the two groups was 1. 62,and 95% confidence interval( CI) was 1. 30-2. 03. No obvious heterogeneity or publication bias was detected. Conclusion The pCR rate of TNBC in NAC is higher than that of HER-2 positive breast cancer.